Literature DB >> 26921804

Persistently Vitreous Culture-Positive Exogenous Bacterial Endophthalmitis.

Ella H Leung1, Ajay E Kuriyan1, Harry W Flynn2, Darlene Miller1, Laura C Huang1.   

Abstract

PURPOSE: To report the clinical settings, bacterial isolates, antibiotic sensitivities, and visual acuity outcomes of patients with persistently positive vitreous cultures after intravitreal antibiotics.
DESIGN: Consecutive, noncomparative case series.
METHODS: setting: Tertiary care center. PATIENT POPULATION: Thirty-six eyes of 36 patients with exogenous endophthalmitis with the same bacterial organism identified on at least 2 consecutive vitreous cultures from 1981 to 2015. OBSERVATION PROCEDURES: Vitreous cultures with intravitreal injections of antibiotics and pars plana vitrectomies with intravitreal antibiotics. MAIN OUTCOME MEASURES: Bacterial isolates, antibiotic sensitivities, visual outcomes.
RESULTS: Thirty-six eyes of 36 patients met the study criteria. The mean follow-up was 26.5 months. The most common clinical settings were after cataract extraction (18/36, 50%) and glaucoma surgery (11/36, 31%). The mean initial visual acuity was 2.16 ± 0.77 logMAR (Snellen equivalent ≈20/2900), and there was no statistically significant change at the final evaluation (2.08 ± 0.97 logMAR, ≈20/1900, P = .72). The most common bacteria were Staphylococcus (11/36, 31%) and Streptococcus (9/36, 25%). Gram-positive bacteria were sensitive to vancomycin (27/27, 100%); gram-negative bacteria were sensitive to amikacin (5/5, 100%). The antibiotic sensitivities were the same on repeat cultures in 34 of 36 patients (94%). The initial treatment was a vitreous culture and intravitreal injection of antibiotics in 28 of 36 patients (78%). The vision at the last follow-up was 20/200 or better in 12 patients (33%) and no light perception in 11 of 36 patients (31%).
CONCLUSIONS: The most commonly identified organisms were gram-positive bacteria. There was good concordance in the antibiotic sensitivities between initial and subsequent cultures. Patients with persistently vitreous culture-positive endophthalmitis had poor visual outcomes.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26921804      PMCID: PMC4870093          DOI: 10.1016/j.ajo.2016.02.017

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  26 in total

1.  Intravitreal antibiotic therapy with vancomycin and aminoglycoside: examination of the retinal toxicity of repetitive injections after vitreous and lens surgery.

Authors:  B S Oum; D J D'Amico; H W Kwak; K W Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

2.  Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial.

Authors:  E Albrecht; J C Richards; T Pollock; C Cook; L Myers
Journal:  Br J Ophthalmol       Date:  2011-02-02       Impact factor: 4.638

3.  Recurrent postoperative endophthalmitis.

Authors:  G A Stern; H M Engel; W T Driebe
Journal:  Cornea       Date:  1990-04       Impact factor: 2.651

4.  Persistent endophthalmitis after intravitreal antimicrobial therapy.

Authors:  A Shaarawy; M G Grand; T A Meredith; H E Ibanez
Journal:  Ophthalmology       Date:  1995-03       Impact factor: 12.079

5.  Initial adhesion and surface growth of Staphylococcus epidermidis and Pseudomonas aeruginosa on biomedical polymers.

Authors:  B Gottenbos; H C van der Mei; H J Busscher
Journal:  J Biomed Mater Res       Date:  2000-05

6.  Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis.

Authors:  I M Gan; J T van Dissel; W H Beekhuis; W Swart; J C van Meurs
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

7.  Growth curve for Propionibacterium acnes.

Authors:  G S Hall; K Pratt-Rippin; D M Meisler; J A Washington; T J Roussel; D Miller
Journal:  Curr Eye Res       Date:  1994-06       Impact factor: 2.424

8.  Vancomycin levels after intravitreal injection. Effects of inflammation and surgery.

Authors:  H E Aguilar; T A Meredith; A el-Massry; A Shaarawy; M Kincaid; J Dick; D J Ritchie; R M Reichley; M K Neisman
Journal:  Retina       Date:  1995       Impact factor: 4.256

9.  Anterior vitrectomy and partial capsulectomy via anterior approach to treat chronic postoperative endophthalmitis.

Authors:  Mete Güler; Turgut Yılmaz
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

10.  Recurrent nontuberculous mycobacterial endophthalmitis: a diagnostic conundrum.

Authors:  Nandini Venkateswaran; Gabrielle Yeaney; Mina Chung; Holly B Hindman
Journal:  Clin Ophthalmol       Date:  2014-05-02
View more
  5 in total

Review 1.  Application Progress of High-Throughput Sequencing in Ocular Diseases.

Authors:  Xuejun He; Ningzhi Zhang; Wenye Cao; Yiqiao Xing; Ning Yang
Journal:  J Clin Med       Date:  2022-06-17       Impact factor: 4.964

2.  Trends in treatment strategies for suspected bacterial endophthalmitis.

Authors:  Greg D Fliney; Paula E Pecen; Jennifer N Cathcart; Alan G Palestine
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-07       Impact factor: 3.117

3.  Atypical Microbiological Feature of Infectious Endophthalmitis on Jeju Island: A 10-Year Study at a Single Tertiary Referral Center.

Authors:  Joong Hyun Park; Dong Yoon Kim; Ahnul Ha; Dae Joong Ma; Hye Jin Lee; Jinho Jeong; Jin Young Kim
Journal:  J Ophthalmol       Date:  2021-03-02       Impact factor: 1.909

4.  Early and complete vitrectomy versus tap and inject in acute post cataract surgery endophthalmitis presenting with hand motion vision; a quasi-experimental study.

Authors:  Seyed Ali Tabatabaei; Soran Aminzade; Aliasghar Ahmadraji; Mohammad Soleimani; Bahram Bohrani Sefidan; Abolfazl Kasaee; Kasra Cheraqpour
Journal:  BMC Ophthalmol       Date:  2022-01-08       Impact factor: 2.209

5.  Endophthalmitis at a tertiary referral center: Characteristics and treatment outcomes over three decades.

Authors:  Wen-Fei Zhang; Xin-Yu Zhao; Li-Hui Meng; Huan Chen; You-Xin Chen
Journal:  Front Cell Dev Biol       Date:  2022-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.